Use the hyperlinks, where available to access additional clinical trial information.
A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy
This is a non-randomised trial evaluating three treatment regimens, across three experimental arms. Participants in Experimental Arm 1 will receive Belvarafenib alone, twice daily (BID), continuous dosing. Participants in Experimental Arm 2 will receive Belvarafenib (at the recommended dose) plus cobimetinib once daily (QD) for 21 days, 7 days off. Participants in Experimental Arm 3 will receive Belvarafenib plus cobimetinib (at the recommended dose) plus Atezolizumab once every 4 weeks (Q4W) followed by an expansion phase.